Ask AI

Applying Emerging B7-H3 ADC Data to Post-Platinum ES-SCLC Decisions

The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the release of new clinical evidence. Watch this video to learn more about the current FDA approvals in ES-SCLC, frontline chemoimmunotherapy options in ES-SCLC, the latest evidence on DLL3-directed T-cell engagers in ES-SCLC, available and emerging treatment options after platinum-based therapy, recent clinical data on the use of investigational B7-H3–directed antibody–drug conjugates, such as ifinatamab deruxtecan, risvutatug rezetecan, tambotatug pelitecan, MHB088C, and elfetabart drozuntecan in ES-SCLC, and a key ongoing phase III trials of B7-H3–directed therapies in ES-SCLC.

Latest Data on Targeting B7 H3 in ES SCLC

Activity Information

Released: November 11, 2026